Research
[World Report] Bundibugyo vaccine trial begins
The Lancet · By Talha Burki ·
The Brief
- A vaccine trial, named Tumaini, has begun in DR Congo to test vaccines against Bundibugyo virus infection.
- Bundibugyo virus infection has reportedly killed more than 5000 people in DR Congo.
- The Lancet World Report by Talha Burki covers the trial launch.
Why it matters
Bundibugyo virus has no licensed vaccine, so the trial's results could inform how outbreaks of this filovirus are controlled in affected regions.
Who’s affected
- Public health researchers working on filovirus outbreaks
- Clinicians and health authorities in DR Congo
- #vaccines
- #bundibugyo virus
- #ebola-like outbreaks
- #clinical trials
- #dr congo
- #public health
The Tumaini trial is hoping to find effective vaccines against Bundibugyo virus infection, which has killed more than 5000 people in DR Congo. Talha Burki reports.
Timeline
The Lancet World Report on the Tumaini trial beginning published
thelancet.com
[World Report] Bundibugyo vaccine trial begins